AO Research Institute Davos, 7270 Davos Platz, Switzerland.
Adv Drug Deliv Rev. 2019 Jun;146:289-305. doi: 10.1016/j.addr.2018.12.015. Epub 2018 Dec 31.
Once damaged, articular cartilage has a limited potential to repair. Clinically, a repair tissue is formed, yet, it is often mechanically inferior fibrocartilage. The use of monolayer expanded versus naïve cells may explain one of the biggest discrepancies in mesenchymal stromal/stem cell (MSC) based cartilage regeneration. Namely, studies utilizing monolayer expanded MSCs, as indicated by numerous in vitro studies, report as a main limitation the induction of type X collagen and hypertrophy, a phenotype associated with endochondral bone formation. However, marrow stimulation and transfer studies report a mechanically inferior collagen I/II fibrocartilage as the main outcome. Therefore, this review will highlight the collagen species produced during the different therapeutic approaches. New developments in scaffold design and delivery of therapeutic molecules will be described. Potential future directions towards clinical translation will be discussed. New delivery mechanisms are being developed and they offer new hope in targeted therapeutic delivery.
一旦受损,关节软骨的修复潜力有限。临床上会形成修复组织,但通常是机械性能较差的纤维软骨。单层扩增细胞与原始细胞的使用可能解释了间充质基质/干细胞(MSC)为基础的软骨再生中最大的差异之一。具体来说,许多体外研究表明,利用单层扩增 MSC 的研究主要受到诱导型 X 胶原和肥大的限制,这种表型与软骨内骨形成有关。然而,骨髓刺激和转移研究报告说,主要结果是机械性能较差的 I/II 型胶原纤维软骨。因此,本综述将重点介绍不同治疗方法中产生的胶原种类。还将描述支架设计和治疗分子传递的新进展。将讨论向临床转化的潜在未来方向。正在开发新的传递机制,为靶向治疗传递带来新的希望。